Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

NCT03097328 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: TAK-228

Sponsor

Bradley A. McGregor, MD

Collaborators

[object Object]